Eisenmenger syndrome: Medical prevention and management strategies

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 12, 2005, Pages 2047-2060

  Budts, Werner ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Eisenmenger syndrome; Endothelin antagonists; Nitric oxide; Prostacyclin; Sildenafil

Indexed keywords

ALLOPURINOL; ANTICOAGULANT AGENT; ARGININE; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; COLCHICINE; CORTICOSTEROID; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; HEPARIN; ILOPROST; IRON; LEVONORGESTREL; METARAMINOL; METHOXAMINE; NIFEDIPINE; NITRIC OXIDE; ORAL CONTRACEPTIVE AGENT; OXYGEN; PARACETAMOL; PHENYLEPHRINE; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNINDEXED DRUG; UNIPROST; VITAMIN K GROUP; WARFARIN;

ARTERIAL PRESSURE; ARTIFICIAL EMBOLISM; BLEEDING DISORDER; BLOOD VISCOSITY; CHOLELITHIASIS; CLINICAL TRIAL; CYANOSIS; DEHYDRATION; DISEASE EXACERBATION; EISENMENGER COMPLEX; ERYTHROCYTOSIS; GOUT; HEART RIGHT LEFT SHUNT; HEART SEPTUM DEFECT; HEMOPTYSIS; HUMAN; HYPERTROPHIC OSTEOARTHROPATHY; HYPERURICEMIA; HYPERVISCOSITY SYNDROME; HYPOTENSION; HYPOXEMIA; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; PARADOXICAL EMBOLISM; PATHOPHYSIOLOGY; PHLEBOTOMY; PULMONARY HYPERTENSION; RESPIRATORY TRACT INFECTION; REVIEW; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM;

DISEASE MANAGEMENT; DRUG DELIVERY SYSTEMS; EISENMENGER COMPLEX; HUMANS; VASODILATOR AGENTS;

EID: 27744523362     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.12.2047     Document Type: Review

References (122)

1. EISENMENGER V: Die angeborenen Defects des Kammerscheidewand des Herzen. Z Klin. Med. (1897) 32:1-28.
2. WOOD P: The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br. Med. J. (1958) 2:701-709.
3. FRIEDMAN WF: Proceedings of National Heart, Lung, and Blood Institute pediatric cardiology workshop: pulmonary hypertension. Pediatr. Res. (1986) 20:811-824.
4. YOUNG D, MARK H: Fate of the patient with the Eisenmenger syndrome. Am. J. Cardiol. (1971) 28(6):658-669.
5. BRITISH CARDIAC SOCIETY WORKING PARTY: Grown-up congenital heart (GUCH) disease: current needs and provision of service for adolescents and adults with congenital heart disease in the UK. Heart (2002) 88(Suppl. 1):i1-i14.
6. VONGPATANASIN W, BRICKNER ME, HILLIS LD, LANGE RA: The Eisenmenger syndrome in adults. Ann. Intern. Med. (1998) 128(9):745-755.
7. SAHA A, BALAKRISHNAN KG, JAISWAL PK et al.: Prognosis for patients with Eisenmenger syndrome of various aetiology. Int. J. Cardiol. (1994) 45(3):199-207.
8. HEATH D, EDWARDS J: The pathology of hypertensive pulmonary vascular disease: a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation (1958) 18:533-547.
9. KIDD L, DRISCOLL DJ, GERSONY WM et al.: Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation (1993) 87(2 Suppl.):I38-I51.
10. HOPKINS WE, OCHOA LL, RICHARDSON GW, TRULOCK EP: Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J. Heart Lung Transplant. (1996) 15(1 Pt 1):100-105.
11. HOPKINS WE, WAGGONER AD: Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. Am. J. Cardiol. (2002) 89(1):34-38.
12. HOPKINS WE: The remarkable right ventricle of patients with Eisenmenger syndrome. Coron. Artery Dis. (2005) 16(1):19-25.
13. PERKETT EA, BADESCH DB, ROESSLER MK, STENMARK KR, MEYRICK B: Insulin-like growth Factor I and pulmonary hypertension induced by continuous air embolization in sheep. Am. J. Respir. Cell Mol. Biol. (1992) 6(1):82-87.
14. PERKETT EA, LYONS RM, MOSES HL, BRIGHAM KL, MEYRICK B: Transforming growth factor-beta activity in sheep lung lymph during the development of pulmonary hypertension. J. Clin. Invest. (1990) 86(5):1459-1464.
15. IKEMOTO Y, TERAGUCHI M, KOBAYASHI Y: Plasma levels of nitrate in congenital heart disease: comparison with healthy children. Pediatr. Cardiol. (2002) 23(2):132-136.
16. GORENFLO M, ZHENG C, POGE A et al.: Metabolites of the L-arginine-NO pathway in patients with left-to-right shunt. Clin Lab. (2001) 47(9-10):441-447.
17. BERGER RM, GEIGER R, HESS J, BOGERS AJ, MOOI WJ: Altered arterial expression patterns of inducible and endothelial nitric oxide synthase in pulmonary plexogenic arteriopathy caused by congenital heart disease. Am. J. Respir. Crit. Care Med. (2001) 163(6):1493-1499.
18. KOMAI H, NAITO Y, AIMI Y, KIMURA H: Nitric oxide synthase expression in lungs of pulmonary hypertensive patients with heart disease. Cardiovasc. Pathol. (2001) 10(1):29-32.
19. STEINHORN RH, FINEMAN JR: The pathophysiology of pulmonary hypertension in congenital heart disease. Artif. Organs (1999) 23(11):970-974.
20. TAKAYA J, TERAGUCHI M, NOGI S, IKEMOTO Y, KOBAYASHI Y: Relation between plasma nitrate and mean pulmonary arterial pressure in ventricular septal defect. Arch. Dis. Child. (1998) 79(6):498-501.
21. IKEMOTO Y, TERAGUCHI M, TAKAYA J, NOGI S, KOBAYASHI Y: Plasma levels of nitric oxide products and endothelin in pulmonary hypertension with congenital heart disease. Acta Paediatr. (1998) 87(6):715-716.
22. BLACK SM, FINEMAN JR, STEINHORN RH, BRISTOW J, SOIFER SJ: Increased endothelial NOS in lambs with increased pulmonary blood flow and pulmonary hypertension. Am. J. Physiol. (1998) 275(5 Pt. 2):H1643-1651.
23. TUDER RM, COOL CD, GERACI MW et al.: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. (1999) 159(6):1925-1932.
24. ADATIA I, BARROW SE, STRATTON PD et al.: Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation (1993) 88(5 Pt 1):2117-2122.
25. BLACK SM, BEKKER JM, MCMULLAN DM et al.: Alterations in nitric oxide production in 8-week-old lambs with increased pulmonary blood flow. Pediatr. Res. (2002) 52(2):233-244.
26. BLACK SM, SANCHEZ LS, MATA-GREENWOOD E et al.: sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Pbysiol. (2001) 281(5):L1051-L1057.
27. OZEROL IH, PAC FA, OZEROL E et al.: Plasma endothelin-1, homocysteine and serum nitric oxide values in patients with left-to-right shunt. Indian Heart J. (2004) 56(6):653-657.
28. BANDO K, VIJAYARAGHAVAN P, TURRENTINE MW et al.: Dynamic changes of endothelin-1, nitric oxide, and cyclic GMP in patients with congenital heart disease. Circulation (1997) 96(9 Suppl. II):346-351.
29. BLACK SM, MATA-GREENWOOD E, DETTMAN RW et al.: Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow. Circulation (2003) 108(13):1646-1654.
30. GORENFLO M, BETTENDORF M, ULMER HE, BROCKMEIER K: Oxygen-mediated pulmonary vasodilation and plasma levels of endothelin-1, atrial natriuretic peptide and cyclic GMP in patients with left-to-right shunt and pulmonary hypertension. Z. Kardiol. (2000) 89(2):100-108.
31. TUTAR HE, IMAMOGLU A, ATALAY S, GUMUS H, AKAR N: Plasma endothelin-1 levels in patients with left-to-right shunt with or without pulmonary hypertension. Int. J. Cardiol. (1999) 70(1):57-62.
32. LUTZ J, GORENFLO M, HABIGHORST M et al.: Endothelin-1- and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease. Clin. Chem. Lab. Med. (1999) 37(4):423-428.
33. ISHIKAWA S, MIYAUCHI T, SAKAI S et al.: Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. J. Thorac. Cardiovasc. Surg. (1995) 110(1):271-273.
34. VINCENT JA, ROSS RD, KASSAB J, HSU JM, PINSKY WW: Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flow. Am. J. Cardiol. (1993) 71(13):1204-1207.
35. CACOUB P, DORENT R, MAISTRE G et al.: Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am. J. Cardiol. (1993) 71(5):448-450.
36. FUSE S, TOMITA H, CHIBA S: Plasma thromboxane B2 concentration in patients with ventricular septal defect and pulmonary hypertension. Jpn. Circ. J. (1998) 62(3):193-197.
37. FUSE S, KAMIYA T: Plasma thromboxane B2 concentration in pulmonary hypertension associated with congenital heart disease. Circulation (1994) 90(6):2952-2955.
38. CELERMAJER DS, CULLEN S, DEANFIELD JE: Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation (1993) 87(2):440-446.
39. BARST RJ, STALCUP SA: Endothelial function in clinical pulmonary hypertension. Chest (1985) 88(4 Suppl.):216S-220S.
40. DAMAS JK, OTTERDAL K, YNDESTAD A et al.: Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation (2004) 110(8):999-1005.
41. STEINHORN RH, RUSSELL JA, LAKSHMINRUSIMHA S et al.: Altered endothelium-dependent relaxations in lambs with high pulmonary blood flow and pulmonary hypertension. Am. J. Physiol. Heart Circ. Physiol (2001) 280(1):H311-H317.
42. LOPES AA, MAEDA NY, GONCALVES RC, BYDLOWSKI SP: Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. Am. Heart J. (2000) 139(4):618-623.
43. HENRIKSSON P, VARENDH G, LUNDSTROM NR: Haemostatic defects in cyanotic congenital heart disease. Br. Heart J. (1979) 41(1):23-27.
44. ALTMAN R, SCAZZIOTA A, ROUVIER J et al.: Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. Clin. Cardiol. (1996) 19(7):549-554.
45. STEELE P, ELLIS JH JR, WEILY HS, GENTON E: Platelet survival time in patients with hypoxemia and pulmonary hypertension. Circulation (1977) 55(4):660-661.
46. PETERS AM, ROZKOVEC A, BELL RN et al.: Platelet kinetics in congenital heart disease. Cardiovasc. Res. (1982) 16(7):391-397.
47. HORIGOME H, HIRAMATSU Y, SHIGETA O, NAGASAWA T, MATSUI A: Overproduction of platelet microparticles in cyanotic congenital heart disease with polycythemia. J. Am. Coll. Cardiol. (2002) 39(6):1072-1077.
48. RABINOVITCH M, ANDREW M, THOM H et al.: Abnormal endothelial Factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation (1987) 76(5):1043-1052.
49. GILL JC, WILSON AD, ENDRES-BROOKS J, MONTGOMERY RR: Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood (1986) 67(3):758-761.
50. LOPES AA, MAEDA NY: Abnormal degradation of von Willebrand factor main subunit in pulmonary hypertension. Eur. Respir. J. (1995) 8(4):530-536.
51. GIDDING SS, STOCKMAN JA III: Erythropoietin in cyanotic heart disease. Am. Heart J. (1988) 116(1 Pt 1):128-132.
52. GIDDING SS, STOCKMAN JA III: Effect of iron deficiency on tissue oxygen delivery in cyanotic congenital heart disease. Am. J. Cardiol. (1988) 61(8):605-607.
53. PERLOFF JK, MARELLI AJ, MINER PD: Risk of stroke in adults with cyanotic congenital heart disease. Circulation (1993) 87(6):1954-1959.
54. LOPES AA, MAEDA NY, EBAID M, CHAMONE DF, PILEGGI F: Effect of intentional hemodilution on platelet survival in secondary pulmonary hypertension. Chest (1989) 95(6):1207-1210.
55. SILVERSIDES CK, GRANTON JT, KONEN E et al.: Pulmonary thrombosis in adults with Eisenmenger syndrome. J. Am. Coll. Cardiol. (2003) 42(11):1982-1987.
56. LOPES AA, CARAMURU LH, MAEDA NY: Endothelial dysfunction associated with chronic intravascular coagulation in secondary pulmonary hypertension. Clin. Appl. Thromb. Hemost. (2002) 8(4):353-358.
57. KOEPKE JA, RODGERS JL, OLLIVIER MJ: Pre-instrumental variables in coagulation testing. Am. J. Clin. Pathol. (1975) 64(5):591-596.
58. KURLAN R, GRIGGS RC: Cyanotic congenital heart disease with suspected stroke. Should all patients receive antibiotics? Arch. Neurol. (1983) 40(4):209-212.
59. YOON W: Embolic agents used for bronchial artery embolisation in massive haemoptysis. Expert Opin. Pharmacother. (2004) 5(2):361-367.
60. YOON W, KIM JK, KIM YH, CHUNG TW, KANG HK: Bronchial and nonbronchial systemic artery embolization for life-threatening hemoptysis: a comprehensive review. Radiographics (2002) 22(6):1395-1409.
61. JEAN-BAPTISTE E: Clinical assessment and management of massive hemoptysis. Crit. Care Med. (2000) 28(5):1642-1647.
62. PERLOFF JK: Systemic complications of cyanosis in adults with congenital heart disease. Hematologic derangements, renal function, and urate metabolism. Cardiol. Clin. (1993) 11(4):689-699.
63. OYA H, NAGAYA N, SATOH T et al.: Haemodynamic correlates and prognostic significance of serum uric acid in adult patients with Eisenmenger syndrome. Heart (2000) 84(1):53-58.
64. FLANAGAN MF, HOURIHAN M, KEANE JF: Incidence of renal dysfunction in adults with cyanotic congenital heart disease. Am. J. Cardiol. (1991) 68(4):403-406.
65. SCOTT-BURDEN T, VANHOUTTE PM: Regulation of smooth muscle cell growth by endothelium-derived factors. Tex. Heart Inst. J. (1994) 21(1):91-97.
66. CHERRY PD, FURCHGOTT RF, ZAWADZKI JV, JOTHIANANDAN D: Role of endothelial cells in relaxation of isolated arteries by bradykinin. Proc Natl Acad Sci USA (1982) 79(6):2106-2110.
67. IGNARRO LJ, BUGA GM, WOOD KS, BYRNS RE, CHAUDHURI G: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA (1987) 84(24):9265-9269.
68. SPERLING RT, CREAGER MA: Nitric oxide and pulmonary hypertension. Coron. Artery Dis. (1999) 10(5):287-294.
69. YUAN XJ, WANG J, JUHASZOVA M, GAINE SP, RUBIN LJ: Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet (1998) 351(9104):726-727.
70. ROSSAINT R, PISON U, GERLACH H, FALKE KJ: Inhaled nitric oxide: its effects on pulmonary circulation and airway smooth muscle cells. Eur. Heart J. (1993) 14(Suppl. I):133-140.
71. GEORGE SJ, BOSCOE MJ: Inhaled nitric oxide for right ventricular dysfunction following cardiac transplantation. Br. J. Clin. Pract. (1997) 51(1):53-55.
72. COSTARD-JACKLE A, HILL I, SCHROEDER JS, FOWLER MB: The influence of preoperative patient characteristics on early and late survival following cardiac transplantation. Circulation (1991) 84(5 Suppl. III):329-337.
73. SITBON O, HUMBERT M, JAGOT JL et al.: Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur. Respir. J. (1998) 12(2):265-270.
74. ROBERTS JD JR, FINEMAN JR, MORIN FC III et al.: Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N. Engl. J. Med. (1997) 336(9):605-610.
75. BEGHETTI M, HABRE W, FRIEDLI B, BERNER M: Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br. Heart J. (1995) 73(1):65-68.
76. ATSUMI N, KANEMOTO S, TERADA Y et al.: [Inhaled nitric oxide for postoperative pulmonary hypertensive crisis in a patient with complete atrioventricular canal associated with Down's syndrome: a case report]. Kyobu Geka (1996) 49(9):729-732.
77. GOMI S, ATSUMI N, TERADA Y et al.: [NO inhalation therapy for post-operative pulmonary hypertensive crisis of the case of truncus arteriosus]. Nippon Kyobu Geka Gakkai Zasshi (1997) 45(7):1061-1065.
78. MURTHY KS, RAO SG, PRAKASH KS et al.: Role of inhaled nitric oxide as a selective pulmonary vasodilator in pediatric cardiac surgical practice. Indian J. Pediatr. (1999) 66(3):357-361.
79. MATSUI J, YAHAGI N, KUMON K et al.: Effects of inhaled nitric oxide on postoperative pulmonary circulation in patients with congenital heart disease. Artif. Organs (1997) 21(1):17-20.
80. DAY RW, HAWKINS JA, MCGOUGH EC, CREZEE KL, ORSMOND GS: Randomized controlled study of inhaled nitric oxide after operation for congenital heart disease. Ann. Thorac. Surg. (2000) 69(6):1907-1912; discussion 1913.
81. BUDTS W, VAN PELT N, GILLYNS H et al.: Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome. Heart (2001) 86(5):553-558.
82. POST MC, JANSSENS S, VAN DE WERE F, BUDTS W: Responsiveness to inhaled nitric oxide is a predictor for midterm survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur. Heart J. (2004) 25(18):1651-1656.
83. BOWYER JJ, BUSST CM, DENISON DM, SHINEBOURNE EA: Effect of long term oxygen treatment at home in children with pulmonary vascular disease. Br. Heart J. (1986) 55(4):385-390.
84. SANDOVAL J, AGUIRRE JS, PULIDO T et al.: Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am. J. Respir. Crit. Care Med. (2001) 164(9):1682-1687.
85. WIMMER M, SCHLEMMER M: Long-term hemodynamic effects of nifedipine on congenital heart disease with Eisenmenger's mechanism in children. Cardiovasc. Drugs Ther. (1992) 6(2):183-186.
86. HOPKINS WE, KELLY DP: Angiotensin-converting enzyme inhibitors in adults with cyanotic congenital heart disease. Am. J. Cardiol. (1996) 77(5):439-440.
87. BARST RJ: Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest (1986) 89(4):497-503.
88. BARST RJ, RUBIN LJ, LONG WA et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. (1996) 334(5):296-302.
89. MCLAUGHLIN VV, GENTHNER DE, PANELLA MM, RICH S: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N. Engl. J. Med. (1998) 338(5):273-277.
90. HIGENBOTTAM T, WHEELDON D, WELLS F, WALLWORK J: Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet (1984) 1(8385):1046-1047.
91. BUSH A, BUSST CM, SHINEBOURNE EA: The use of oxygen and prostacyclin as pulmonary vasodilators in congenital heart disease. Int. J. Cardiol. (1985) 9(3):267-274.
92. ROSENZWEIG EB, KERSTEIN D, BARST RJ: Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation (1999) 99(14):1858-1865.
93. FERNANDES SM, NEWBURGER JW, LANG P et al.: Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am. J. Cardiol. (2003) 91(5):632-635.
94. SIMONNEAU G, BARST RJ, GALIE N et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. (2002) 165(6):800-804.
95. OLSCHEWSKI H, WALMRATH D, SCHERMULY R et al.: Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann. Intern. Med. (1996) 124(9):820-824.
96. RIMENSBERGER PC, SPAHR-SCHOPFER I, BERNER M et al.: Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation (2001) 103(4):544-548.
97. HALLIOGLU O, DILBER E, CELIKER A: Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am. J. Cardiol. (2003) 92(8):1007-1009.
98. OKANO Y, YOSHIOKA T, SHIMOUCHI A, SATOH T, KUNIEDA T: Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet (1997) 349(9062):1365.
99. NAGAYA N, UEMATSU M, OKANO Y et al.: Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J. Am. Coll. Cardiol. (1999) 34(4):1188-1192.
100. GALIE N, HUMBERT M, VACHIERY JL et al.: Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. (2002) 39(9):1496-1502.
101. BARST RJ, MCGOON M, MCLAUGHLIN V et al.: Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2003) 41(12):2119-2125.
102. CHANNICK RN, SIMONNEAU G, SITBON O et al.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 358(9288):1119-1123.
103. SITBON O, BADESCH DB, CHANNICK RN et al.: Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest (2003) 124(1):247-254.
104. RUBIN LJ, BADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2002) 346(12):896-903.
105. CHRISTENSEN DD, MCCONNELL ME, BOOK WM, MAHLE WT: Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am. J. Cardiol. (2004) 94(2):261-263.
106. BARST RJ, LANGLEBEN D, FROST A et al.: Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. (2004) 169(4):441-447.
107. BOGDAN M, HUMBERT M, FRANCOUAL J et al.: Urinary cGMP concentrations in severe primary pulmonary hypertension. Thorax (1998) 53(12):1059-1062.
108. SCHULZE-NEICK I, HARTENSTEIN P, LI J et al.: Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation (2003) 108 (Suppl. 1:II):167-173.
109. MICHELAKIS ED, TYMCHAK W, NOGA M et al.: Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation (2003) 108(17):2066-2069.
110. ROSENTHAL E: Sildenafil use in patients with the Eisenmenger syndrome. Circulation (2004) 109(16):e197; author reply e197.
111. TRULOCK EP, COOPER JD, KAISER LR et al.: The Washington University-Barnes Hospital experience with lung transplantation. Washington University Lung Transplantation Group. JAMA (1991) 266(14):1943-1946.
112. LUPINETTI FM, BOLLING SF, BOVE EL et al.: Selective lung or heart-lung transplantation for pulmonary hypertension associated with congenital cardiac anomalies. Ann. Thorac. Surg. (1994) 57(6):1545-1548; discussion 1549.
113. LOVELL AT: Anaesthetic implications of grown-up congenital heart disease. Br. J. Anaesth. (2004) 93(1):129-139.
114. SEIFERT-KLAUSS V, KAEMMERER H, BRUNNER B, SCHNEIDER KT, HESS J: [Contraception in patients with congenital heart defects]. Z. Kardiol. (2000) 89(7):606-611.
115. GLEICHER N, MIDWALL J, HOCHBERGER D, JAFFIN H: Eisenmenger's syndrome and pregnancy. Obstet. Gynecol. Surv. (1979) 34(10):721-741.
116. WEISS BM, ZEMP L, SEIFERT B, HESS OM: Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J. Am. Coll. Cardiol. (1998) 31(7):1650-1657.
117. SIU SC, COLMAN JM: Heart disease and pregnancy. Heart (2001) 85(6):710-715.
118. LUST KM, BOOTS RJ, DOORIS M, WILSON J: Management of labor in Eisenmenger syndrome with inhaled nitric oxide. Am. J. Obstet. Gynecol. (1999) 181(2):419-423.
119. GOODWIN TM, GHERMAN RB, HAMEED A, ELKAYAM U: Favorable response of Eisenmenger syndrome to inhaled nitric oxide during pregnancy. Am. J. Obstet. Gynecol. (1999) 180(1 Pt 1):64-67.
120. GEOHAS C, MCLAUGHLIN VV: Successful management of pregnancy in a patient with eisenmenger syndrome with epoprostenol. Chest (2003) 124(3):1170-1173.
121. LACASSIE HJ, GERMAIN AM, VALDES G et al.: Management of Eisenmenger syndrome in pregnancy with sildenafil and L-arginine. Obstet. Gynecol. (2004) 103(5 Pt 2):1118-1120.
122. HUMBERT M, SITBON O, SIMONNEAU G: Treatment of pulmonary arterial hypertension. N. Engl. J. Med. (2004) 351(14):1425-1436.